Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.49 |
| ▸ | CCKBR | P32239 | 13/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15083484 | 1.00 | DPP3 (0.49) | DPP3CCKBR | |
| SCHEMBL15083539 | 1.00 | DPP3 (0.49) | DPP3CCKBR | |
| SCHEMBL27231561 | 1.00 | DPP3 (0.49) | DPP3CCKBR | |
| SCHEMBL16288402 | 1.00 | DPP3 (0.49) | DPP3CCKBR | |
| SCHEMBL31684012 | 1.00 | DPP3 (0.49) | DPP3CCKBR | |
| SCHEMBL23140697 | 0.93 | DPP3 (0.46) | DPP3CCKBR | |
| SCHEMBL31683977 | 0.93 | DPP3 (0.46) | DPP3CCKBR | |
| SCHEMBL31683972 | 0.93 | DPP3 (0.46) | DPP3CCKBR | |
| SCHEMBL15083480 | 0.93 | DPP3 (0.46) | DPP3CCKBR | |
| SCHEMBL15083530 | 0.93 | DPP3 (0.46) | DPP3CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | DPP3 88/4885CCKBR 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.